Daewoong Pharmaceutical Supplies AI Bed Monitoring System "thynC" to Smart Ward at Samsung Medical Center

Daewoong Pharmaceutical announced on July 20 that, in collaboration with SIRS and Sky Labs, it has supplied the AI-powered bed monitoring system "thynC"—which now features blood pressure monitoring—to the Smart Ward at Samsung Medical Center, launching its pilot operation.

A scene showing real-time monitoring of inpatient vital signs through the smart bed monitoring system 'Think'. Daewoong Pharmaceutical

This deployment is part of Samsung Medical Center's ongoing "Smart Ward" initiative. The hospital has converted two rooms within its main building into smart wards serving as digital transformation testbeds and is planning to gradually enhance digital patient experiences by upgrading its ward monitoring systems.

Within the smart ward, thynC is responsible for monitoring key vital signs, including electrocardiogram (ECG), blood pressure, and oxygen saturation.

The version of thynC introduced into Samsung Medical Center’s smart ward is an upgraded system that integrates the existing smart bed monitoring platform with the ring-type continuous blood pressure monitor, "Carton". When patients wear this ultra-small, wearable device, critical physiological data—including ECG, oxygen saturation, and blood pressure—are collected in real time. This data is transmitted to a central monitoring station, enabling medical staff to continuously track patients’ conditions on the ward 24 hours a day.

According to the company, the AI technology analyzes these vital signs and can rapidly alert medical staff to warning signs such as malignant arrhythmias that often occur before cardiac arrest or death. Additionally, the company explained that it is expected to improve patients’ sleep environments by reducing the need for frequent nighttime measurements of vital signs, while also boosting the work efficiency of nurses.

Separately from the smart ward, Daewoong Pharmaceutical signed a contract earlier this year to introduce thynC into the cardiology ward at Samsung Medical Center. The company aims to complete installation of the system—focusing on ECG and oxygen saturation monitoring—for 39 beds within the third quarter of this year.

Recently, as tertiary hospitals are treating a growing proportion of critically ill and emergency patients, there is an increasing need for comprehensive monitoring of patient conditions even in general wards. Continuous monitoring is essential for patients transferred from intensive care units, for those recovering from complex surgeries, and for high-risk cardiovascular patients, even if they are admitted to general wards. The company explained that wearable sensors and AI-powered smart bed monitoring systems, which miniaturize traditional measuring equipment, allow for uninterrupted, around-the-clock observation of patient conditions, supporting the expansion of this system into general wards as well.

Daewoong Pharmaceutical stated that the supply to Samsung Medical Center will serve as a catalyst for expanding thynC to other major tertiary hospitals in Korea. Currently, thynC has been introduced in 16 tertiary hospitals nationwide. The company also announced plans to evolve it into an integrated digital healthcare platform by linking it with a variety of digital healthcare solutions, including those that monitor blood pressure and blood glucose.

A Daewoong Pharmaceutical official stated, "Given that Samsung Medical Center was ranked No.1 in Korea (No.26 worldwide) in Newsweek’s 'World’s Best Hospitals 2026' and is the first in the world to achieve HIMSS Digital Level 7, the adoption of thynC in the hospital’s next-generation smart ward is especially meaningful." The official added, "Based on thynC, Daewoong Pharmaceutical aims to establish a smart hospital model that provides precise clinical decision support for physicians and a safe inpatient environment for patients."

This content was produced with the assistance of AI translation services.